FIG. 4.
OSI-027 and gemcitabine synergism against pancreatic cancer cells. Transformed (PANC-1 or MIA PaCa-2lines) (A, B) or primary (C) pancreatic cancer cells were either left untreated (“C”), or stimulated with OSI-027 (50 nM) and/or gemcitabine (100 μM) for 72 h, cell survival was analyzed by the CellTiter-Glo assay. Severe combined immunodeficiency mice were ear tagged and randomized into four different groups (n=10 for each group): vehicle control, OSI-027 (25 mg/kg, p.o.), gemcitabine (25 mg/kg, i.p.), and OSI-027 plus gemcitabine. Treatments are mentioned in Materials and Methods. Tumor volume (in cm3) (D) was recorded every week for a total of 4 weeks. Mice survival at week 7 was also presented (E, three individual experiments). Data are presented as mean±SE. *p<0.05 versus “C”/vehicle group, #p<0.05 versus gemcitabine only group.